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THE VASOCONSTRICTOR AND PILOERECTOR EFFECT IN HUMAN
SKIN OF DOPAMINE AND NORMETANEPHRINE AS COMPARED
WITH NORADRENALINE*
HALVOR MOLLER, M.D.
Noradrenaline (norepinephrine), the main
transmittor at postganglionic sympathetic
nerve terminals, is a powerful vasoconstrictor
and piloerector. The minimal concentration for
eliciting vasoconstriction after intracutaneous
injection Was recently reported by Stoughton
et cii. (1) to be 10. From the aspect of
molecular structure those authors concluded
that the presence of at least one free hydroxyl
group on the phenyl ring was required for the
compound to induce a considerable vasocon-
striction.
It was the aim of the present study to
further evaluate the relationship between the
molecular structure of noradrenaline and its
activity in the skin. For that purpose the
vasoconstrictor and piloerector effect in man
of intracutaneously injected noradrenaline was
compared with those of its precursor dopamine
and its main metabolite normetanephrine.
For the biosynthesis of noradrenaline
the amino acid 3, 4-dihydroxyphenylalanine
(DOPA) is first decarboxylated to dopamine
(Fig. 1). This reaction is catalyzed by the
enzyme DOPA decarboxylase. Dopamine is
further hydroxylated to noradrenaline by
dopainine-/3-oxidase. Noradrenaline is metabo-
lized mainly by catechol-O-inethyl transferase
to form normetanephrine. This sequence of
formation and breakdown of noradrenaline may
evidently take place in the skin proper, since
the activity of DOPA decarboxylase (2),
dopamine-/3-oxidase (3), and catechol-O-methyl
transferase (4, 5), has recently been demon-
strated in that tissue.
MATERIAL AND METHODS
Doparnine hydrochloride, 1-noradrenaline hi-
tartrate and normetanephrine base were used; all
values given refer to the base. All solutions were
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'NSD 1055 was kindly furnished by Mr. D. J.
Drain, Smith & Nephew Research, Ltd, Harlow,
England.
prepared with saline freshly before use. Fivefold
serial dilutions were prepared from 1/1,000 to
1/3,125,000. In some cases dopamine 1/1,000 was
injected also with the addition of NSD 1055, an
inhibitor of dopamine-j3-oxidase.' One ml syringes
and needles no. 18 (gauge 25) were used and 0.05
ml was injected intracutaneously. Twelve healthy
volunteers (medical students) were injected with
the test solutions in vertical rows on the back
alongside the vertebral column. The position of
the rows was changed from one case to another.
Reactions were read 30 minutes later. In order
to enhance the contrast between a blanched area
and the surrounding skin this latter was painted
with a vasodilating solution containing tetra-
hydrofurfuryl nicotinate (Trafuril®, Ciba) ; this
treatment did not influence the cutaneous effect of
the injected compounds. The injected areas were
inspected for vasoconstriction evidenced by blanch-
ing and for piloerection evidenced by follicular
reaction, "cutis anserina". For an exact estimate
of the blanched areas their contour was copied
on a thin plastic film, which was photographed
against a millimeter graph paper. The picture ob-
tained was magnified, cut out and weighed, and
the area was calculated after comparison with a
standard.
RESULTS
Intracutaneously injected noradrenaline in-
duced vasoconstriction in the minimum con-
centration of 1/625,000 in 7 of the 12 subjects
studied; in 1/125,000 in the other 5. The mean
of the lowest amounts of noradrenaline eliciting
blanching of the skin in this study corresponds
to 0.12 pg. The log dose-response curve is given
in Figure 2.
The lowest concentration of noradrenaline
provoking vasoconstriction and piloerection as
compared with that of dopamine and normeta-
mmephrine is shown in Figures 3 and 4. Vaso-
constriction was induced with dopamine in a
minimum concentration about 80 times stronger
than that of noradrenaline and with normeta-
nephrine about 500 times stronger than that
of noradrenaline. With the concentration of
1/1,000 the mean values of blanched areas were,
for noradrenaline 114.0 11 sq mm, for
dopamine 16.9 3 sq mm and for normeta-
nephrine 13.8 3 sq mm.
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The strong vasoconstrictor effect of nor-
adrenaline, the postganglionic sympathetic
transmittor, was confirmed in the present
work. The relationship in the log dose-response
curve was next to linear (Fig. 2). In the skin
the site of action of topically applied catechol
arnines seems to be the precapillary sfincter,
presumably at the level of the metarteriole
(6). A venoconstriction in the subpapillary
plexus probably occurs as well (6).
Normetanephrine was a very poor vasocon-
strictor when injected into human skin (Fig.
3). The methylation of one of the two hy-
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FIG. 2. Blanched areas induced by different con- 4
centrations of noradrenaline after intracutaneous
injection in man. Mean values from twelve sub- 2
jects are pointed out and connected. The barsindicate standard errors of the mean.
For each substance tested, slightly higher
minimum concentrations were needed to induce
piloerection than vasoconstriction (Figs. 3 and
4). Comparing noradrenaline and dopamine as
for piloerector potency, the difference was a
little less than for vasoconstrictor capacity.
The reverse may be said for the difference be-
tween noradrenaline and normetanephrine: in
seven of the twelve subjects tested no piloerec-
tion at all was observed with normetanephrine
1/1,000.
The addition of NSD 1055 to dopamine did
not influence the vasoconstrictor and piloerec-
tor effect of this amine.
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FIG. 3. The distribution among twelve subjects
of the minimum concentrations of doparnmne, nor-
adrenaline and normetanephrine giving vasocon-
stnction in the skin.
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FIG. 1. The structural formulas of DOPA, dopa-
mine, noradrenaline and normetanephrine.
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accordance with the present finding in human
skin of a vasoconstrictor potency of norineta-
nephrine about 500 times weaker than that of
noradrenaline.
A definite vasoconstrictor effect of intra-
cutaneously injected doparnine about 80 times
weaker than that of noradrenaline, was regis-
tered (Fig. 3). Since dopamine may be
metabolized to noradrenaline by skin tissue
(3) this vasoconstriction might possibly be
caused by newly formed noradrenaline. The
effect, however, was not abolished by an
inhibitor of dopamine--oxidase, and thus
seemed to be due to the action of dopamine
itself.
The vasoactivity, in general, of dopamine
seems more complex than that of nor-
adrenaline. Thc effect of dopamine evidently
possesses a constrictor as well as a dilator
component. This pressor-depressor response is
dependent upon the dose, low doses giving a
depressor response and high doses vasopression
(11, 12). In man the effect of dopamine on
arterial blood pressure has been reported to be
about 50 times weaker than that of noradrenal-
me (11). The influence on peripheral resistence
was rather a moderating one, in contrast to
that of noradrenaline. By intravenous injection
of dopamine, no skin pallor indicative of
cutaneous vasoconstriction was observed. This
discrepancy, in comparison with the present
results obtained by intracutaneous injection of
dopamine, may be explained by the low amounts
reaching the skin vessels following an intrave-
nous administration.
There was an approximate parallelism be-
tween the concentrations of the three amines
tested giving piloerection (Fig. 4) and those
giving vasoconstriction (Fig. 3). The slightly
NORMETANEPHRINE weaker piloerector effect of the compounds
may be explained by the registration method
being less distinct. Confusing results were re-
cently reported after intra-arterial injections of
dopamine in man (11) : piloerection was re-
corded in the forearm with dopamine but not
with other catechol ainines in spite of the fact
that these amines are piloerector by intra-
cutaneous injection.
It may be concluded that the strong vaso-
constrictor and piloerector effect of nor-
adrenaline is dependent to a larger extent upon
two free hydroxyl groups on the phenyl ring
droxyl groups in the phenyl ring thus un-
plies an effectivc inactivation. The weak vaso-
active effect of this methylated derivative of
noradrenaline is fully comparable with that of
histamine (7). Normetanephrine has earlier
been tested in man for its general vaso-
pressor effect by intravenous infusion. With a
dose of 1 mg/mm. no change in the arterial
blood pressure was, however, obtained (8). In
animal experiments the vasopressor effect of
norinetanephrine has been reported to be con-
siderably weaker than that of noradrenaline:
in the dog 500 times (8) in the cat 600 times
(9); in the rabbit 800 times (9); in the rat
1000 times (10). These results are in good
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Fm. 4. The distribution among twelve subjects
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than on the hydroxyl group of the side-chain.
With regard to the two effects tested, 3-0-
methylation of noradrenaline implies an effec-
tive inactivation.
SUMMARY
The vasoconstrictor and piloerector effect in
man of noradrenaline was compared with those
of its precursor dopamine and its main me-
tabolite norrnetanephrine. In comparison with
noradrenaline, dopamine was about 80 times
weaker and normetanephrine about 500 times
weaker.
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